Pacific Capital Partners Ltd Decreases Stock Holdings in Becton, Dickinson and Company $BDX

Pacific Capital Partners Ltd lessened its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 31.2% in the third quarter, HoldingsChannel.com reports. The fund owned 29,250 shares of the medical instruments supplier’s stock after selling 13,250 shares during the period. Becton, Dickinson and Company comprises approximately 6.1% of Pacific Capital Partners Ltd’s portfolio, making the stock its 4th biggest holding. Pacific Capital Partners Ltd’s holdings in Becton, Dickinson and Company were worth $5,475,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in BDX. Brighton Jones LLC lifted its position in shares of Becton, Dickinson and Company by 98.2% during the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after buying an additional 877 shares during the last quarter. Empowered Funds LLC raised its stake in Becton, Dickinson and Company by 20.4% during the first quarter. Empowered Funds LLC now owns 7,977 shares of the medical instruments supplier’s stock worth $1,827,000 after acquiring an additional 1,354 shares in the last quarter. Modern Wealth Management LLC lifted its holdings in shares of Becton, Dickinson and Company by 44.4% in the first quarter. Modern Wealth Management LLC now owns 1,321 shares of the medical instruments supplier’s stock worth $303,000 after acquiring an additional 406 shares during the last quarter. Voya Investment Management LLC boosted its stake in shares of Becton, Dickinson and Company by 1.4% in the 1st quarter. Voya Investment Management LLC now owns 66,337 shares of the medical instruments supplier’s stock valued at $15,195,000 after purchasing an additional 906 shares in the last quarter. Finally, Apella Capital LLC boosted its stake in shares of Becton, Dickinson and Company by 4.9% in the 2nd quarter. Apella Capital LLC now owns 1,616 shares of the medical instruments supplier’s stock valued at $279,000 after purchasing an additional 76 shares in the last quarter. 86.97% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, EVP Michael David Garrison sold 629 shares of the business’s stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $196.03, for a total value of $123,302.87. Following the transaction, the executive vice president owned 13,105 shares in the company, valued at $2,568,973.15. The trade was a 4.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Bertram L. Scott sold 217 shares of the company’s stock in a transaction on Friday, November 7th. The shares were sold at an average price of $176.58, for a total transaction of $38,317.86. Following the sale, the director directly owned 35,816 shares in the company, valued at $6,324,389.28. This trade represents a 0.60% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 1,052 shares of company stock valued at $201,235 in the last three months. Insiders own 0.40% of the company’s stock.

Analyst Ratings Changes

BDX has been the subject of a number of research analyst reports. Wall Street Zen cut shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Stifel Nicolaus upped their price target on shares of Becton, Dickinson and Company from $210.00 to $215.00 and gave the stock a “buy” rating in a report on Wednesday, January 7th. Jefferies Financial Group raised their price objective on Becton, Dickinson and Company from $215.00 to $220.00 and gave the company a “buy” rating in a report on Wednesday, December 10th. Royal Bank Of Canada upped their target price on Becton, Dickinson and Company from $202.00 to $210.00 and gave the stock a “sector perform” rating in a report on Wednesday, December 17th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research note on Wednesday, October 8th. Four analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat, Becton, Dickinson and Company has an average rating of “Hold” and an average price target of $207.64.

Becton, Dickinson and Company Stock Performance

Shares of Becton, Dickinson and Company stock opened at $201.38 on Wednesday. The stock has a market cap of $57.37 billion, a price-to-earnings ratio of 34.54, a P/E/G ratio of 2.24 and a beta of 0.23. Becton, Dickinson and Company has a twelve month low of $162.29 and a twelve month high of $251.99. The company’s fifty day moving average is $194.06 and its 200 day moving average is $188.80. The company has a quick ratio of 0.64, a current ratio of 1.11 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, November 6th. The medical instruments supplier reported $3.96 EPS for the quarter, topping the consensus estimate of $3.92 by $0.04. Becton, Dickinson and Company had a return on equity of 16.42% and a net margin of 7.68%.The firm had revenue of $5.89 billion for the quarter, compared to the consensus estimate of $5.91 billion. During the same period in the previous year, the business earned $3.81 EPS. The business’s quarterly revenue was up 8.3% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 14.750-15.050 EPS. Sell-side analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, December 31st. Investors of record on Monday, December 8th were issued a $1.05 dividend. The ex-dividend date was Monday, December 8th. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. This represents a $4.20 annualized dividend and a yield of 2.1%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 72.04%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.